Investigative research into companies, leadership, and markets— uncovering hidden risks and validating commercial assumptions
Clarity in a Complex World
Strategic decisions—whether entering a new market, partnering with a counterparty, or defending a competitive position—require more than surface-level data. Public filings and press releases rarely tell the full story. Hidden ownership structures, undisclosed conflicts, and opaque market dynamics can derail deals, trigger regulatory scrutiny, or erode competitive advantage.
Mintz Group delivers deep, discreet investigative research into companies, markets, and actors worldwide. We validate counterparties, map influence networks, and uncover pressure points—helping clients make informed decisions, anticipate competitor moves, and protect commercial interests.
“Mintz gave us clarity on a market we thought we understood—before we committed capital.”
A major private equity fund engaged Mintz to evaluate an investment target with operations in multiple jurisdictions. Our investigation uncovered undisclosed beneficial ownership tied to politically exposed persons and regulatory risks in one country. This insight enabled the investor to carve out the high-risk business unit from the transaction, renegotiate terms, and proceed with confidence.
A global construction firm engaged Mintz to evaluate a rival consortium’s past performance. Mintz uncovered recurring engineering delays, partner disagreements, and consistent bidding patterns. These insights enabled our client to sharpen its bid strategy and secure the contract.
Before entering a new market, a consumer goods company retained Mintz to map local actors and regulatory dynamics. Our findings exposed cartel-like behavior among distributors and flagged corruption risks, leading the client to delay entry and renegotiate terms.
Mintz conducted a global IP sweep for a luxury brand facing counterfeit threats. We identified key production hubs and distribution channels, enabling targeted enforcement actions that reduced infringement by 40% within six months.
